Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

A global genome damage score predictive of lung cancer patients outcome

Oncogene volume 25, pages 4491–4494 (2006)Cite this article

Abstract

Genome damage is a hallmark of human cancer. Efforts at assessing the impact of genome damage on tumor phenotype and patients outcome have focused on measurements of the relative DNA content in tumor cells compared to normal cells and the assessment of allelic loss at single or multiple selected loci that are thought to harbor genes important in cancer biology. We adapted a global, high-resolution genotyping method for determination of global and unbiased allelic loss. We generated a score, termed global genome damage score (GGDS), that is a continuous variable from zero to one and a measure of the extent of damaged DNA in individual tumors. In 71 patients with completely resected non-small-cell lung cancer, the GGDS ranged from 0.0006 to 0.5530 with a median value of 0.0401 indicating that between 0.06 and 55.3% of the genome has allelic loss. Patients with high scores (>0.04) had a significantly worse outcome than those with low scores (median overall survival time 35.5 vs >120.0 months, P=0.006 log-rank test; median disease-free survival 28.3 vs >120.0 months, P=0.003 log-rank test). This suggests that the clinical behavior of lung tumors with low GGDS is relatively benign whereas tumors with high GGDS are aggressive resulting in early death of patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Ali IU, Lidereau R, Theillet C, Callahan R . (1987). Science 238: 185–188.

  • Auer G, Eriksson E, Azavedo E, Caspersson T, Wallgren A . (1984). Cancer Res 44: 394–396.

  • Barlogie B, Johnson DA, Smallwood L, Raber MN, Maddox AM, Latreille J et al. (1982). Cancer Genet Cytogenet 6: 17–28.

  • Bell GI, Selby MJ, Rutter WJ . (1982). Nature 295: 31–35.

  • Bepler G, Gautam A, McIntyre LM, Beck AF, Chervinsky DS, Kim YC et al. (2002). J Clin Oncol 20: 1353–1360.

  • Botstein D, White RL, Skolnick MH, Davis RW . (1980). Am J Genet 32: 314–331.

  • Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL et al. (1983). Nature 305: 779–784.

  • Contal C, O'Quigley J . (1999). Comput Stat Data Anal 30: 253–270.

  • Fearon ER, Vogelstein B . (1990). Cell 61: 759–767.

  • Fong K, Zimmerman P, Smith P . (1995). Cancer Res 55: 220–223.

  • Hoeijmakers J . (2001). Nature 411: 366–374.

  • Jeffreys AJ, Wilson V, Thein SL . (1985). Nature 314: 67–73.

  • Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P et al. (1994). N Engl J Med 331: 213–221.

  • Mandrekar JN . (2003). SUGI Proc 28: 261–280.

  • Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Sugio K et al. (1996). Clin Cancer Res 2: 1185–1189.

  • Nakamura Y, Leppert M, O'Connell P, Wolff R, Holm T, Culver M et al. (1987). Science 235: 1616–1622.

  • Royle NJ, Clarkson RE, Wong Z, Jeffreys AJ . (1988). Genomics 3: 352–360.

  • Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M et al. (1988). N Engl J Med 319: 525–532.

  • Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y et al. (1989). Science 244: 207–211.

  • Volm M, Drings P, Mattern J, Sonka J, Vogt-Moykopf I, Wayss K . (1985). Cancer 56: 1396–1403.

  • Wolley RC, Schreiber K, Koss LG, Karas M, Sherman A . (1982). J Natl Cancer Inst 69: 15–22.

  • Yunis JJ . (1983). Science 221: 227–236.

Download references

Acknowledgements

This work was supported in part by grants from the Department of Defense (National Functional Genomics Center) and the National Cancer Institute (R01 CA102726 and U01 CA101222).

Author information

Authors and Affiliations

  1. H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    Z Zheng, A Cantor & G Bepler

Authors
  1. Z Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Cantor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Bepler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Bepler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zheng, Z., Cantor, A. & Bepler, G. A global genome damage score predictive of lung cancer patients outcome. Oncogene 25, 4491–4494 (2006). https://doi.org/10.1038/sj.onc.1209476

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209476

Keywords

Search

Advanced search

Quick links